Catalog No.
Product Name
Application
Product Information
Citations
-
E3 Ligase Ligand-Linker Conjugate
Thalidomide-piperidin-4-ylmethanol is an E3 ligase ligand-linker conjugate known for its affinity to cereblon (CRBN). This compound is instrumental in the synthesis of proteolysis-targeting chimeras (PROTACs), facilitating targeted protein degradation. It is valuable for research applications in directed protein modulation and cellular pathway analysis. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-azetidine-C-OH is an E3 ligase ligand-linker conjugate that features a CRBN-based ligand combined with a linker moiety. This compound facilitates the design and synthesis of PROTACs, which are innovative bifunctional molecules capable of targeting and ubiquitinating specific proteins for degradation. With its potential applications in targeted protein degradation studies, Thalidomide-azetidine-C-OH serves as a valuable tool for researchers investigating cellular signaling pathways and protein homeostasis. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-piperazine hydrochloride is an E3 ligase ligand-linker conjugate that incorporates a Cereblon (CRBN)-based ligand along with a piperazine linker. This compound is instrumental in the synthesis of Proteolysis Targeting Chimeras (PROTACs), facilitating targeted protein degradation. It plays a critical role in advancing research on targeted therapies for various cancers and other diseases by modulating protein levels within cellular environments. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide 4'-alkylC3-azide is an E3 ligase ligand-linker conjugate designed for use with cereblon (CRBN). This compound facilitates the development of proteolysis-targeting chimeras (PROTACs) by linking E3 ligase activity to targeted protein degradation. It is valuable for research applications in cellular signaling and therapeutic development, enabling innovative strategies in targeted protein modulation. -
E3 Ligase Ligand-Linker Conjugate
(S)-Glutarimide-amide-Py-piperidine-CHO is an E3 ligase ligand-linker conjugate designed to engage cereblon (CRBN). This compound facilitates the formation of PROTAC molecules, enabling targeted protein degradation in cellular systems. Its utility in biochemistry offers potential for applications in drug development and therapeutic research focused on modulating protein levels within the cell. -
E3 Ligase Ligand-Linker Conjugate
(3S)Lenalidomide-5-methylpiperazine benzenesulfonate is an E3 ligase ligand-linker conjugate that incorporates a cereblon (CRBN)-based ligand. This compound serves as a crucial building block for the synthesis of proteolysis-targeting chimeras (PROTACs), which enable targeted protein degradation. It is instrumental in research applications focused on modulating protein levels and investigating cellular pathways associated with diseases such as cancer. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-acetylene-C2-NH2 is an E3 ligase ligand-linker conjugate designed to engage cereblon (CRBN) for targeted protein degradation. This compound serves as a crucial component for the synthesis of proteolysis-targeting chimeras (PROTACs), facilitating the selective degradation of proteins by the ubiquitin-proteasome system. Its unique structure enables researchers to explore novel therapeutic strategies and efficacy in various biological contexts. -
E3 Ligase Ligand-Linker Conjugate
Desamino lenalidomide-C2-COOH is an E3 ligase ligand-linker conjugate that features a cereblon (CRBN)-based ligand and a flexible linker. This compound is designed for use in the synthesis of PROTACs (proteolysis-targeting chimeras), enabling targeted protein degradation. Its capacity to engage E3 ligases makes it a valuable tool for research in cellular protein regulation and therapeutic targeted intervention. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-C10-NH2 is an E3 ligase ligand-linker conjugate designed to facilitate targeted protein degradation. This compound integrates the (S,R,S)-AHPC-derived VHL ligand with a robust linker, promoting the formation of BET-targeted PROTACs. It serves as an essential tool for researchers investigating ubiquitin-proteasome system pathways and advancing therapeutic strategies through targeted protein modulation. -
E3 Ligase Ligand-Linker Conjugates
Lenalidomide-PEG3-iodine is an E3 ligase ligand-linker conjugate that combines a Lenalidomide-derived cereblon ligand with a three-unit polyethylene glycol (PEG) linker. This compound facilitates the synthesis of proteolysis-targeting chimeras (PROTACs), including the potent BTK degrader SJF620, which demonstrates a DC50 of 7.9 nM. Lenalidomide-PEG3-iodine is valuable for research in targeted protein degradation and the development of innovative therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-C6-NH2 dihydrochloride is an E3 ligase ligand-linker conjugate that combines the VHL ligand derived from VH032 with a C6 linker, specifically designed for the development of AKT PROTAC degraders. This compound facilitates targeted protein degradation by recruiting E3 ligases, thereby offering significant utility in studies of protein turnover and cellular signaling pathways. It serves as a valuable tool for researchers investigating the effects of synthetic PROTACs in therapeutic contexts. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-C8-NH2 dihydrochloride is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound incorporates the VH032-derived VHL ligand, facilitating the recruitment of E3 ligases for degradation of target proteins. Its linker is specifically optimized for use in AKT PROTACs, making it valuable for research in protein degradation pathways and therapeutic development. This compound is referenced as XF038-164A, example 8, and is derived from patent WO2019173516A1. -
E3 Ligase Ligand-linker Conjugate
(S,R,S)-AHPC-C3-NH2 TFA is an E3 ligase ligand-linker conjugate designed for use in proteolysis-targeted chimera (PROTAC) technology. This compound features the VH032-derived VHL ligand, facilitating targeted degradation of specific substrates. It is instrumental in synthesizing various PROTACs, including UNC6852, which targets EED for bivalent degradation, making it valuable for studies in cellular regulation and protein homeostasis. -
E3 Ligase Ligand-Linker Conjugates
Lenalidomide-C5-NH2 TFA is an E3 ligase ligand-linker conjugate that targets the Cereblon (CRBN) protein. This compound facilitates the recruitment of CRBN, enabling the development of PROTACs for targeted protein degradation applications, including MDM2 PROTAC degraders. Its ability to link specific ligands for protein degradation makes it a valuable tool in chemical biology and therapeutic development research. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-C10-NH2 dihydrochloride is a specialized E3 ligase ligand-linker conjugate, incorporating the (S,R,S)-AHPC-derived VHL ligand. This compound functions as a key component in the development of BET-targeted PROTACs, facilitating targeted protein degradation in cellular systems. Its application in chemical biology allows for the exploration of protein function through enhanced specificity for E3 ligase engagement, making it a valuable reagent for researchers investigating protein modulation mechanisms. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-PEG1-NH2 dihydrochloride is an E3 ligase ligand-linker conjugate featuring a VHL ligand designed for the ubiquitin-proteasome system, combined with a PROTAC linker. This compound is instrumental in the development of PROTACs, facilitating targeted protein degradation and elucidating cellular processes. Its utility extends to studies exploring protein interactions and degradation pathways, making it a valuable tool in chemical biology and drug discovery research. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-amido-PEG4-C2-NH2 is an engineered E3 ligase ligand-linker conjugate that features a thalidomide-derived cereblon ligand combined with a PEG4 linker. This compound is designed to facilitate targeted protein degradation via PROTAC (Proteolysis Targeting Chimera) technology, enabling the selective modulation of protein levels in cellular systems. Its applications include studying protein degradation pathways and developing therapeutic strategies that leverage the ubiquitin-proteasome system for enhanced drug efficacy. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-PEG2-Tos is an E3 ligase ligand-linker conjugate that incorporates a cereblon ligand connected through a diethylene glycol (PEG2) spacer. This compound facilitates targeted protein degradation by recruiting E3 ligases, enabling the selective degradation of specific substrates. It is especially useful in research focused on the modulation of protein levels and the development of targeted therapeutics for various diseases, including cancer. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-C4-NH2 is an engineered E3 ligase ligand-linker conjugate that features the (S,R,S)-AHPC-based von Hippel-Lindau (VHL) ligand. This compound is designed to facilitate the development of EED-targeted PROTACs by promoting the ubiquitination and subsequent degradation of specific protein targets. Its ability to selectively engage E3 ligases makes it a valuable tool for probing protein turnover and elucidating the dynamics of cellular signaling pathways. -
E3 Ligase Ligand-Linker Lonjugate
(S,R,S)-AHPC-O-Ph-PEG1-NH-Boc is an E3 ligase ligand-linker conjugate designed to facilitate targeted protein degradation through the EED pathway. This compound effectively engages E3 ligases, enabling the development of PROTACs (proteolysis-targeting chimeras) for precise modulation of protein levels in various biological systems. Its utility spans applications in chemical biology and therapeutic research focused on protein degradation and regulation. -
E3 Ligase Ligand-Linker Conjugates
VHL Ligand-Linker Conjugates 15 functions as an E3 ligase ligand-linker conjugate, incorporating a von Hippel-Lindau (VHL) ligand paired with a PROTAC linker. This compound is designed to facilitate the development of PROTACs, enabling targeted protein degradation. Its application spans various areas of research, particularly in therapeutic discovery and cellular regulation studies where modulation of protein levels is essential. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-Me-C10-NH2 is a synthesized conjugate designed for E3 ligase targeting, incorporating a von Hippel-Lindau (VHL) ligand and a linker. This compound serves as a key component in creating proteolysis-targeting chimeras (PROTACs), facilitating the selective degradation of intracellular proteins. Its application in research can help elucidate the roles of specific proteins in various biological processes and disease pathways. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-amido-C4-amido-C6-NH-Boc is a synthesized E3 ligase ligand-linker conjugate that employs the Pomalidomide-derived cereblon ligand for targeted protein degradation. This compound is designed to enhance the specificity and efficacy of PROTAC (Proteolysis Targeting Chimera) technology, facilitating the targeted ubiquitination and subsequent degradation of selected proteins. Its applications include investigating cellular pathways and therapeutic strategies in various diseases, including cancer. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-amido-C4-amido-PEG2-C2-NH-Boc is an E3 ligase ligand-linker conjugate that features a Pomalidomide-derived cereblon ligand combined with a two-unit polyethylene glycol (PEG) linker. This compound is designed for use in PROTAC (Proteolysis Targeting Chimeras) technology, facilitating targeted protein degradation. Its structure enhances molecular stability and solubility, making it suitable for research applications focused on protein regulation and therapeutic development. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-C6-O-C5-O-C4-COOH is an E3 ligase ligand-linker conjugate designed to engage cereblon via its Pomalidomide moiety. This compound serves as a versatile tool for the synthesis of PROTACs (Proteolysis Targeting Chimeras), facilitating targeted protein degradation in various biological research applications. Its unique structural features enhance its potential for specific ligand binding and effectiveness in manipulating cellular protein levels, making it suitable for investigations into protein regulation and therapeutic development. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-amino-PEG5-NH2 is a conjugate designed for E3 ligase modulation, utilizing a Pomalidomide-derived ligand targeting cereblon. This compound features a PEG5 linker, facilitating its application in PROTAC technology. It is valuable for studies in targeted protein degradation and related therapeutic strategies. -
E3 Ligase Ligand-linker Conjugate
(S,R,S)-AHPC-Bromooctanoic acid is an E3 ligase ligand-linker conjugate that incorporates (S,R,S)-AHPC and a corresponding linker. This compound functions as a ligand for the von Hippel-Lindau (VHL) protein, facilitating the recruitment of VHL in targeted protein degradation applications. It serves as a crucial intermediate in the synthesis of complete PROTAC (proteolysis targeting chimera) molecules for advanced research into targeted therapeutics and protein modulation. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-C7-amine is an E3 ligase ligand-linker conjugate that combines the VHL ligand VH032 with a specialized linker for enhanced targeting of estrogen-related receptor α (ERRα). This compound is designed for use in the development of PROTAC degraders, allowing for selective degradation of specific proteins through the ubiquitin-proteasome pathway. Its applications extend to studies in targeted protein degradation and the modulation of cellular pathways associated with ERRα. -
MAGL Ligand-Linker Conjugate
MAGL Ligand-Linker Conjugate 1 is a conjugate designed to target monoacylglycerol lipase (MAGL) through its ligand-linker structure. This reagent serves as an essential component for the synthesis of PROTAC MAGL degrader-1, facilitating targeted protein degradation in research applications focused on MAGL inhibition. Its utility extends to studies involving lipid metabolism and related signaling pathways. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-NHCO-C-O-C5-N3 is a conjugate designed for E3 ligase applications, integrating a specific ligand with a useful linker. This compound is instrumental in the synthesis of PROTACs, particularly for the targeted degradation of SARS-CoV-2 Mpro, enabling innovative research into viral protein regulation. Its utility in complex molecular biology studies makes it a valuable tool for advancing therapeutic development strategies. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-CO-C-piperazine is a ligand-linker conjugate targeting E3 ligases. This compound facilitates the formation of protein ubiquitination complexes, making it valuable for studying protein degradation pathways and developing targeted protein degradation therapies. Its unique structure enables specific interactions with E3 ligases, providing insights into their role in various cellular processes. This reagent is instrumental in chemical biology and drug discovery applications focused on modulating ubiquitin-proteasome system functions. -
E3 Ligase Ligand-Linker Conjugate
Piperidin-4-amine-C5-O-C1-Thalidomide is an E3 ligase ligand-linker conjugate designed for use in the development of PROTACs (proteolysis-targeting chimeras). This compound facilitates targeted protein degradation by linking a substrate protein to an E3 ligase, enhancing the specificity and efficacy of the degradation process. Its utility in chemical biology makes it a valuable tool for applications in targeted drug discovery and therapeutic research. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-linker Conjugate 48 is an innovative conjugate designed to target E3 ubiquitin ligases, facilitating the development of Proteolysis Targeting Chimeras (PROTACs). This reagent enables researchers to create effective PROTACs by enhancing the ubiquitin-proteasome system's activity, allowing for the selective degradation of target proteins. Its application is crucial for studies involving targeted protein degradation and therapeutic discovery. -
E3 Ligase Ligand-linker Conjugate
(S,R,S)-AHPC-CO-C4-bromine is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications using PROTAC (Proteolysis Targeting Chimeras) technology. This compound facilitates the recruitment of specific target proteins for ubiquitination by E3 ligases, thereby promoting their subsequent degradation. Its structural features enhance the efficiency of PROTAC constructs, making it a valuable tool for studying protein dynamics and therapeutic interventions in various disease models. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-PEG3-C2-NH2 hydrochloride is a synthetic conjugate designed as an E3 ligase ligand-linker. This compound features a Thalidomide-derived cereblon ligand, effectively facilitating targeted protein degradation through PROTAC technology. It is instrumental in research applications focusing on the modulation of cellular protein levels and the exploration of E3 ligase-related pathways. -
LCL-PEG3-N3 Decoy Oligonucleotide Ligand
LCL-PEG3-N3 is a decoy oligonucleotide ligand targeting E3 ligases, facilitating the development of chimeric molecules such as LCL-ER(dec) for the degradation of estrogen receptors. As a versatile click chemistry reagent, it features an azide functional group, enabling copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules. Additionally, LCL-PEG3-N3 can participate in strain-promoted alkyne-azide cycloaddition (SPAAC) reactions when combined with DBCO or BCN-modified entities. This compound is valuable in chemical biology applications and protein degradation studies. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-C2-Br is an E3 Ligase Ligand-Linker conjugate that functions as a versatile tool for targeted protein degradation. This compound is designed to facilitate the synthesis of PROTAC AR Degrader-8, enabling researchers to investigate the modulation of protein levels via the ubiquitin-proteasome system. Its unique structure supports the development of innovative approaches for therapeutic intervention in various diseases, particularly in oncology research. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-C10-NHBoc is an E3 ligase ligand-linker conjugate that utilizes the (S,R,S)-AHPC-based VHL ligand along with a designed linker for BET-targeted PROTAC applications. This compound facilitates the selective degradation of target proteins through the recruitment of E3 ligases. Its structural design makes it a valuable tool for studies in targeted protein degradation and the development of innovative therapeutic strategies in cancer research. -
E3 Ligase Ligand-Linker Conjugate
8-Hydroxyoctanoic acid-thalidomide is an E3 ligase ligand-linker conjugate that facilitates the targeted degradation of proteins via the ubiquitin-proteasome pathway. This compound exhibits potent activities that support the development of targeted protein degradation strategies in chemical biology research. Additionally, it can be employed in the synthesis of Lw13 for further investigative studies into protein modulation and therapeutic applications. -
Ligand for E3 Ligase
Pomalidomide-C11-NH2 hydrochloride is a potent ligand targeting the E3 ubiquitin ligase cereblon (CRBN). This compound facilitates the recruitment of CRBN, enabling the development of proteolysis-targeting chimeras (PROTACs) for targeted protein degradation. Its utility in drug discovery and molecular biology research makes it a valuable tool for studying protein regulation and associated pathways. -
Von-Hippel-Lindau Pprotein Ligand
VH 101 phenol-alkylC4-amine dihydrochloride is a ligand for the von-Hippel-Lindau (VHL) protein, functioning as an E3 ligase ligand with an integrated alkylC4 linker. This compound is instrumental in proteolysis-targeting chimera (PROTAC) research, enabling targeted degradation of specific proteins to study their biological functions and implications in various diseases. Its unique design allows for enhanced modulation of protein interactions, making it a valuable tool in molecular and cellular biology research. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 116 is designed as a ligand-linker conjugate targeting E3 ubiquitin ligases. This compound facilitates the synthesis of PROTAC SMARCA2/4-degrader-28, enabling selective protein degradation through the ubiquitin-proteasome system. Its applications are particularly significant in studying mechanisms of protein regulation and the development of targeted therapeutics in cancer research. -
E3 Ligase Ligand-Linker Conjugate
AHPC-PEG6-CH2COOH is a conjugate designed to facilitate interactions with E3 ligases, featuring a von Hippel-Lindau (VHL) ligand linked through a 6-unit polyethylene glycol (PEG) chain. This reagent serves as a valuable tool in the synthesis of PROTAC CMP98, enabling targeted protein degradation applications in chemical biology research. Its unique structure allows for improved solubility and bioavailability, making it suitable for various studies involving targeted protein modulation. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-CO-PEG3-NHBoc is an E3 ligase ligand-linker conjugate designed for the synthesis of PROTAC G9a/GLP degrader 1. This compound facilitates targeted protein degradation through the selective degradation of G9a and GLP, demonstrating significant anti-cancer activity. Its application is pivotal in advancing research in protein modulation and therapeutic development in oncology. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-C2-PEG3-NH2 is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound facilitates the synthesis of PROTACs, such as USP39 Degrader-1, enabling the selective degradation of specific protein targets through the ubiquitin-proteasome system. Its structure includes a polyethylene glycol (PEG) linker, enhancing solubility and pharmacokinetic properties for more effective biological activity in research studies. -
Multikinase Degrader
Azido-PEG2-VHL is a multikinase degrader that serves as a versatile building block for the synthesis of PROTACs (proteolysis-targeting chimeras). This compound features an azide functionality, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with alkyne-functionalized molecules, such as those containing DBCO or BCN groups. Its application in targeted protein degradation makes it a valuable tool in chemical biology research. -
E3 Ubiquitin Ligase Ligand-Linker Conjugate
Thalidomide 4'-ether-PEG2-azide is a click chemistry-modified derivative of Thalidomide that functions as an E3 ubiquitin ligase ligand-linker conjugate. It features an azide group capable of participating in copper-catalyzed azide-alkyne cycloaddition reactions, making it suitable for conjugation with alkynyl-containing molecules. This reagent is particularly valuable in the development of Proteolysis Targeting Chimeras (PROTACs), enabling targeted protein degradation and advanced therapeutic strategies in cancer research and other areas of drug discovery. -
E3 Ligase Ligand-Linker Conjugates
E3 Ligase Ligand-linker Conjugate 133 is a synthesized conjugate comprising an E3 ligase ligand and a linker, functioning as a crucial intermediate in the development of the PROTAC molecule pan-KRAS degrader 4. This compound facilitates targeted protein degradation by leveraging the ubiquitin-proteasome system, making it essential for studies related to targeted cancer therapeutics and protein modulation. Its application in PROTAC research highlights its potential in advancing therapeutic strategies against malignancies associated with KRAS mutations. -
E3 Ubiquitin Ligase Ligand-Linker Conjugate
Thalidomide-O-C5-azide is a specialized E3 ubiquitin ligase ligand-linker conjugate, derived from the CRBN inhibitor Thalidomide. This compound features an azide group capable of participating in copper-catalyzed azide-alkyne cycloaddition reactions, making it suitable for use in the synthesis of PROTACs. Thalidomide-O-C5-azide facilitates targeted protein degradation, making it a valuable tool in chemical biology and therapeutic research applications. -
E3 Ligase Ligand-Linker Conjugates Chemical
(S,R,S)-AHPC-Me-decanedioic acid is an E3 ligase ligand-linker conjugate that facilitates the development of proteolysis targeting chimeras (PROTACs). This compound enables targeted protein degradation by linking specific ligands to E3 ligases, supporting research into cellular regulation and therapeutic interventions. It is suitable for applications involving the modulation of protein levels in various biological systems.
